EXIT-CVD
Project factsheets
Learn more about the projects supported by IHI as well as the Innovative Medicines Initiative (IMI).
Displaying 28 projects and 2 programmes
GENz-trials: Revolutionizing clinical trials to optimize assessment of healthcare innovations
Verification and validation of a biomarker panel that identifies individuals at high risk to develop Crohn’s disease allowing interception of full-blown disease development
Patient AI treatment hub
The next leap in cancer care: combining multi-modality and spectral imaging, advanced therapies, robotics and AI to enable standardized, precise interventional oncology treatments for cancer patients
Research in Europe and diversity inclusion
Seamless integration of image guidance to break down the barriers and enhance the efficiency of minimally invasive and hybrid neurosurgical care
Antibiotic distribution and recovery in tissue
Antimicrobial Resistance Accelerator
Corona accelerated R&D in Europe
Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen
Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen: phase II
Bringing a prophylactic Ebola vaccine to licensure
Novel Gram-negative antibiotic now
Development of Impentri, an intravenous imatinib formulation for COVID-19 acute respiratory distress syndrome (ARDS)
Translational approaches to disease modifying therapy of type 1 diabetes - HARVESTing the fruits of INNODIA
Parkinson disease with mild cognition impairment treated with nicotinic agonist drug
PERtussIS COrrelates of Protection Europe
Proton versus photon therapy for esophageal cancer - a trimodality strategy
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Saracatinib trial to prevent FOP
Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments
Academia and industry united innovation and treatment for tuberculosis
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
Combatting bacterial resistance in Europe - molecules against Gram negative infections
European prevention of Alzheimer’s dementia consortium
Inhaled antibiotics in bronchiectasis and cystic fibrosis
New Drugs for Bad Bugs
Molecular reclassification to find clinically useful biomarkers for systemic autoimmune diseases
